Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.28229
Mirko Barone
{"title":"Clinical Effects of Postoperative Parenteral GlutamineDipeptide Supplementation in Surgical Intensive Care Unit Patients: A Systematic Review and Meta-Analysis","authors":"Mirko Barone","doi":"10.14744/ejmo.2023.28229","DOIUrl":"https://doi.org/10.14744/ejmo.2023.28229","url":null,"abstract":"","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.56385
Mustafa Mahir Ulgu
Objectives: This study aimed to deepen our understanding of AFP's role in disease, evaluate its current use as a screening tool for HCC and germ cell tumors, and explore potential improvements in screening protocols to enhance early detection and improve patient outcomes. Methods: The study analyzed the data of AFP test requests between 2017-2021, comprising a total of 15.618.083 tests from 3,213,258 individuals. The AFP levels were determined using the immunoassay method and the results were transferred to the National Health Database, which is referred to as e-pulse by the Ministry of Health. This database encompasses the health records of patients who have sought medical services from all healthcare institutions in Turkey, including their demographic characteristics, laboratory data, medication usage, comorbidities, and other health-related records. Results: The results showed that the average number of tests per person was 4.86, and the number of tests per 100,000 population was 18,899. While the number of AFP tests increased in the earlier years, a noticeable decrease was observed in 2020 and 2021. Comparing genders, the test was more frequently requested for women, with a ratio of 1.46-1.61 for female/male test numbers across the years. AFP testing was most common in the 18-64 age group, followed by patients over 65, while the 0-17 age group had the least number of tests. The study also examined the effectiveness of AFP as a screening tool for HCC. It was found that AFP alone had limitations as a screening test, as its sensitivity varied between 58% and 80%. Conclusion: In conclusion, this study sheds light on the role of AFP as a tumor marker in HCC and germ cell tumors. Although it has limitations as a standalone screening tool, AFP testing, in combination with other diagnostic methods, contributes to the early detection and monitoring of HCC.
{"title":"Advancing Screening Protocols: Investigating the Role of Alpha-Fetoprotein Supported by Turkish Ministry of Health Data in Hepatocellular Carcinoma and Germ Cell Tumors","authors":"Mustafa Mahir Ulgu","doi":"10.14744/ejmo.2023.56385","DOIUrl":"https://doi.org/10.14744/ejmo.2023.56385","url":null,"abstract":"Objectives: This study aimed to deepen our understanding of AFP's role in disease, evaluate its current use as a screening tool for HCC and germ cell tumors, and explore potential improvements in screening protocols to enhance early detection and improve patient outcomes. Methods: The study analyzed the data of AFP test requests between 2017-2021, comprising a total of 15.618.083 tests from 3,213,258 individuals. The AFP levels were determined using the immunoassay method and the results were transferred to the National Health Database, which is referred to as e-pulse by the Ministry of Health. This database encompasses the health records of patients who have sought medical services from all healthcare institutions in Turkey, including their demographic characteristics, laboratory data, medication usage, comorbidities, and other health-related records. Results: The results showed that the average number of tests per person was 4.86, and the number of tests per 100,000 population was 18,899. While the number of AFP tests increased in the earlier years, a noticeable decrease was observed in 2020 and 2021. Comparing genders, the test was more frequently requested for women, with a ratio of 1.46-1.61 for female/male test numbers across the years. AFP testing was most common in the 18-64 age group, followed by patients over 65, while the 0-17 age group had the least number of tests. The study also examined the effectiveness of AFP as a screening tool for HCC. It was found that AFP alone had limitations as a screening test, as its sensitivity varied between 58% and 80%. Conclusion: In conclusion, this study sheds light on the role of AFP as a tumor marker in HCC and germ cell tumors. Although it has limitations as a standalone screening tool, AFP testing, in combination with other diagnostic methods, contributes to the early detection and monitoring of HCC.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"156 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.14880
Wilson Jiang
{"title":"Time to Prioritise Quality Over Quantity in Prehabilitation Trials: A Literature Review","authors":"Wilson Jiang","doi":"10.14744/ejmo.2023.14880","DOIUrl":"https://doi.org/10.14744/ejmo.2023.14880","url":null,"abstract":"","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135214173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.42261
G. Ravikumar
. Objectives: A standardized nomenclature to report Antinuclear antibody(ANA) is given by the International consensus on ANA pattern (ICAP). The cytoplasmic, mitotic and rare nuclear patterns are infrequently reported.The study was done to understand the clinical significance and frequency of these unconventional patterns in our population. Methods: Retrospective one year blinded study of ANA patterns in serum samples. Results: Of the 4730 samples, 4568 were included after deleting 162 repeat samples. ANA positivity was seen in 673 cases (14.7%). Cytoplasmic patterns were found in 184 cases (27.3%) and mitotic pattern in 16 (2.4%) cases. Exclusive cytoplasmic patterns were seen in 100 cases (14.3%) and exclusive mitotic pattern in 14 cases (2.08%). Rare nuclear patterns were seen in 30 cases (4.5%).The most common exclusive cytoplasmic pattern was filamentous(n=39), whereas the common cytoplasmic pattern associated with nuclear pattern (mixed pattern) was cytoplasmic homogeneous (AC-19). The rare nuclear patterns included Topo-I (n=9), nuclear envelope (n=5), multiple (n=6) and few (n=8) nuclear dots. While some of the common cytoplasmic patterns like filamentous and homogeneous were more frequent in AIDs the uncommon patterns showed varied clinical associations. Conclusion: The study demonstrates the clinical significance of reporting exclusive and mixed non nuclear ANA patterns on IIF as many of these have known autoimmune associations.
{"title":"Non-Nuclear and Rare Nuclear ANA Patterns in Indirect Immunoflourescence Testing and their Clinical Associations","authors":"G. Ravikumar","doi":"10.14744/ejmo.2023.42261","DOIUrl":"https://doi.org/10.14744/ejmo.2023.42261","url":null,"abstract":". Objectives: A standardized nomenclature to report Antinuclear antibody(ANA) is given by the International consensus on ANA pattern (ICAP). The cytoplasmic, mitotic and rare nuclear patterns are infrequently reported.The study was done to understand the clinical significance and frequency of these unconventional patterns in our population. Methods: Retrospective one year blinded study of ANA patterns in serum samples. Results: Of the 4730 samples, 4568 were included after deleting 162 repeat samples. ANA positivity was seen in 673 cases (14.7%). Cytoplasmic patterns were found in 184 cases (27.3%) and mitotic pattern in 16 (2.4%) cases. Exclusive cytoplasmic patterns were seen in 100 cases (14.3%) and exclusive mitotic pattern in 14 cases (2.08%). Rare nuclear patterns were seen in 30 cases (4.5%).The most common exclusive cytoplasmic pattern was filamentous(n=39), whereas the common cytoplasmic pattern associated with nuclear pattern (mixed pattern) was cytoplasmic homogeneous (AC-19). The rare nuclear patterns included Topo-I (n=9), nuclear envelope (n=5), multiple (n=6) and few (n=8) nuclear dots. While some of the common cytoplasmic patterns like filamentous and homogeneous were more frequent in AIDs the uncommon patterns showed varied clinical associations. Conclusion: The study demonstrates the clinical significance of reporting exclusive and mixed non nuclear ANA patterns on IIF as many of these have known autoimmune associations.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73233714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.69719
S. Koca
Objectives: Enzalutamide(ENZ) is an effective hormonal treatment modality in mCRPC. It can be used before or after docetaxel(DTX) in this setting. Herein, we aimed to show the efficacy of ENZ before or after DTX use and the factors predicting the efficacy. Methods: We retrospectively collected the data of 320 patients from 12 centers who were treated with ENZ in mCRPC. The initial stage, age, line of treatment, serum prostate-specific antigen (PSA) levels before ENZ treatment and at nadir, site of metastasis, gleason score were evaluated. Results: Median age of 320 patients were 69. At a median follow-up of 56 months, 271/320 (84.7%) disease progression and 230/320(71.9%) death had been observed. Median PFS was 11(8.9-13)) and median OS was 25(22.1-27.8) months in all patients group. Median PFS was 10(7.4-12.5) months, 11(8-13.9) months in pre-DTX and post-DTX groups respectively. Median OS was higher in the post-DTX group than the pre-DTX group (28(25.7-30.2) vs 19(15.0-22.9-46.6) (p:0.000). Gleason score ≥ 8 (HR 0.59, 95%CI 0.46-0.77, p=0.00), presence of non-visceral metastasis (HR 0.72, 95%CI 0.53-0.97, p=0.031), initial PSA value<43(median) (HR 0.70, 95%CI 0.54-0.91, p=0.009), PSA at nadir <2 (HR 0.61, 95%CI 0.44-0.85, p=0.004), >50% decline in PSA (HR 0.27, 95%CI 0.19-0.36, p=0.000) significantly predicted ENZ response regarding rPFS. Conclusion: ENZ has shown equal efficacy before and after DTX treatment in mCRPC regarding rPFS. But OS rate was significantly better in the pre-DTX group. Therefore, we recommend starting with DTX in patients who can tolerate chemotherapy in mCRPC setting.
{"title":"Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study","authors":"S. Koca","doi":"10.14744/ejmo.2023.69719","DOIUrl":"https://doi.org/10.14744/ejmo.2023.69719","url":null,"abstract":"Objectives: Enzalutamide(ENZ) is an effective hormonal treatment modality in mCRPC. It can be used before or after docetaxel(DTX) in this setting. Herein, we aimed to show the efficacy of ENZ before or after DTX use and the factors predicting the efficacy. Methods: We retrospectively collected the data of 320 patients from 12 centers who were treated with ENZ in mCRPC. The initial stage, age, line of treatment, serum prostate-specific antigen (PSA) levels before ENZ treatment and at nadir, site of metastasis, gleason score were evaluated. Results: Median age of 320 patients were 69. At a median follow-up of 56 months, 271/320 (84.7%) disease progression and 230/320(71.9%) death had been observed. Median PFS was 11(8.9-13)) and median OS was 25(22.1-27.8) months in all patients group. Median PFS was 10(7.4-12.5) months, 11(8-13.9) months in pre-DTX and post-DTX groups respectively. Median OS was higher in the post-DTX group than the pre-DTX group (28(25.7-30.2) vs 19(15.0-22.9-46.6) (p:0.000). Gleason score ≥ 8 (HR 0.59, 95%CI 0.46-0.77, p=0.00), presence of non-visceral metastasis (HR 0.72, 95%CI 0.53-0.97, p=0.031), initial PSA value<43(median) (HR 0.70, 95%CI 0.54-0.91, p=0.009), PSA at nadir <2 (HR 0.61, 95%CI 0.44-0.85, p=0.004), >50% decline in PSA (HR 0.27, 95%CI 0.19-0.36, p=0.000) significantly predicted ENZ response regarding rPFS. Conclusion: ENZ has shown equal efficacy before and after DTX treatment in mCRPC regarding rPFS. But OS rate was significantly better in the pre-DTX group. Therefore, we recommend starting with DTX in patients who can tolerate chemotherapy in mCRPC setting.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85168638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.29445
Qiang Wu
. In
。在
{"title":"Comprehensive Analysis of Biologic and Prognostic Implication for ZNF536 in Pan-Cancer","authors":"Qiang Wu","doi":"10.14744/ejmo.2023.29445","DOIUrl":"https://doi.org/10.14744/ejmo.2023.29445","url":null,"abstract":". In","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76022110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.25905
A. Lalwani
{"title":"Radio-Pathological Correlation of Suspected Malignant Thyroid Nodules using Elastography strain ratio and Bethesda Classification for Thyroid Cytopathology","authors":"A. Lalwani","doi":"10.14744/ejmo.2023.25905","DOIUrl":"https://doi.org/10.14744/ejmo.2023.25905","url":null,"abstract":"","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"48 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75166096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.53961
M. Ammendola
Compelling evidence indicates that GC is a heterogeneous dis-ease on the basis of anatomic site, histopathology, gene Objectives: Tumor proliferation is guided by neoangiogenesis; microvascular density (MVD) in the tumor micro-envi-ronment increases with the action of different immune system stromal cells such as the mast cells (MCs). Methods: We evaluated Ki-67 proliferation rate, MCs positive to tryptase (MCPT), and MVD in a series of 85 gastric cancer (GC) tissue samples from patients undergoing radical surgery. Results: In tumor tissue, a significant correlation between Ki-67 expression, MCPT, and MVD was found through Pearson t-test analysis (p ranged from 0.01 to 0.03). Conclusion: Ki-67 expression and MVD may indicate the survival prognosis of patients and MCPT could repre-sent a biological marker of radical surgery and angiogenesis. Furthermore, MCPT could be consid-ered as a target of novel anti-angiogenic therapies in GC patients.
{"title":"Ki-67 Expression, Mast Cells Positive to Tryptase, and Angiogenesis in Gastric Cancer Patients Undergoing Radical Surgery","authors":"M. Ammendola","doi":"10.14744/ejmo.2023.53961","DOIUrl":"https://doi.org/10.14744/ejmo.2023.53961","url":null,"abstract":"Compelling evidence indicates that GC is a heterogeneous dis-ease on the basis of anatomic site, histopathology, gene Objectives: Tumor proliferation is guided by neoangiogenesis; microvascular density (MVD) in the tumor micro-envi-ronment increases with the action of different immune system stromal cells such as the mast cells (MCs). Methods: We evaluated Ki-67 proliferation rate, MCs positive to tryptase (MCPT), and MVD in a series of 85 gastric cancer (GC) tissue samples from patients undergoing radical surgery. Results: In tumor tissue, a significant correlation between Ki-67 expression, MCPT, and MVD was found through Pearson t-test analysis (p ranged from 0.01 to 0.03). Conclusion: Ki-67 expression and MVD may indicate the survival prognosis of patients and MCPT could repre-sent a biological marker of radical surgery and angiogenesis. Furthermore, MCPT could be consid-ered as a target of novel anti-angiogenic therapies in GC patients.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"11 11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78396798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.35261
Hai-hong Lin
and their related molecules have little benefit in improving survival, prognosis, recurrence and metastasis despite tumor size shrinkage. Compared with these routine treatment methods, the traditional Chinese medicine (TCM) cancer therapy based on TCM theory, in which the cancer initiation is regarded as disorder of human body system, focuses on the events impacting the gene rather than the gene itself. In fact, it is necessary but not sufficient for cancer initiation and progression to activate OCG or inactivate TSG, which exhibit oncogene or tumor-suppressor property depending on the biological context. In TCM theory, lung and large intestine are external-internal relations of each other, which are physiologically related and pathologically affected each other. Hence, the use of a classical laxative medicine rhubarb for lung cancer treatment is in line with TCM theory. Emodin as the major component of rhubarb represents the multi-targeting therapeutic mechanisms of TCM in multiple disease treatment including anti-cancer. There are some reviews on microscopic and inner mechanisms of emodin in cancer treatment, our previous study confirmed lung cancer-preventing effect of lung cancer. Here, we summarize the real mechanisms of emodin treating lung cancer based on system pharmacology, mainly focusing on the resolution of intrinsic pathological inducers, which will provide a solid foundation to understand cancer pathogenesis and formulate cancer therapy.
{"title":"The Real Mechanisms of Emodin Treating Lung Cancer Based on System Pharmacology","authors":"Hai-hong Lin","doi":"10.14744/ejmo.2023.35261","DOIUrl":"https://doi.org/10.14744/ejmo.2023.35261","url":null,"abstract":"and their related molecules have little benefit in improving survival, prognosis, recurrence and metastasis despite tumor size shrinkage. Compared with these routine treatment methods, the traditional Chinese medicine (TCM) cancer therapy based on TCM theory, in which the cancer initiation is regarded as disorder of human body system, focuses on the events impacting the gene rather than the gene itself. In fact, it is necessary but not sufficient for cancer initiation and progression to activate OCG or inactivate TSG, which exhibit oncogene or tumor-suppressor property depending on the biological context. In TCM theory, lung and large intestine are external-internal relations of each other, which are physiologically related and pathologically affected each other. Hence, the use of a classical laxative medicine rhubarb for lung cancer treatment is in line with TCM theory. Emodin as the major component of rhubarb represents the multi-targeting therapeutic mechanisms of TCM in multiple disease treatment including anti-cancer. There are some reviews on microscopic and inner mechanisms of emodin in cancer treatment, our previous study confirmed lung cancer-preventing effect of lung cancer. Here, we summarize the real mechanisms of emodin treating lung cancer based on system pharmacology, mainly focusing on the resolution of intrinsic pathological inducers, which will provide a solid foundation to understand cancer pathogenesis and formulate cancer therapy.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81879683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Amniotic Fluid-Derived Stem Cells: A Promising Resource for Cardiomyogenesis","authors":"S. Sisakhtnezhad","doi":"10.14744/ejmo.2023.47139","DOIUrl":"https://doi.org/10.14744/ejmo.2023.47139","url":null,"abstract":"DOI: 10.14744/ejmo.2023.47139 EJMO 2023;7(2):103–119","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85576405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：